GlaxoSmithKline CR`s Total Debt Growth reached -100 % in 2014. This is 400 % less than in the previous year.
Buy Total Debt Growth data for GlaxoSmithKline Czech Republic.
$19.99Buy all data for GlaxoSmithKline Czech Republic.
Buy annual subscriptions for all our products.
| Company | Unit | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| Amgen Czech Republic | % | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | 137,021 | 80.5 | ... | |
| Bayer Czech Republic | % | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | -68.3 | 428 | |||
| GlaxoSmithKline Czech Republic | % | ... | ... | ... | 74.0 | -33.7 | 33.3 | -100 | ... | ... | ... | |||||||
| Merck Czech Republic | % | ... | ... | 24.2 | -12.8 | 18.1 | -85.0 | -100 | ... | ... | ||||||||
| Novartis Czech Republic | % | ... | 24.4 | -73.0 | -100 | ... | -100 | ... | ||||||||||
| Pfizer Czech Republic | % | ... | ... | ... | ... | ... | ... | ... | -100 | ... | ... | ... | ... | ... | ||||
| Roche Czech Republic | % | ... | ... | ... | ... | -100 | ... | 88.9 | 89.9 | 21.8 | ... | |||||||
| Sanofi-Aventis Czech Republic | % | ... | ... | ... | ... | -7.86 | 21.0 | -37.4 | -46.6 | -14.2 | ||||||||
| Walmark | % | ... | ... | ... | -36.1 | 327 | -1.50 | 7.02 | 61.0 |
Helgi Library 
